Indicated for: variceal bleeding; hepatorenal syndrome
Route of administration: injectable
Substance: terlipressin (somatostatin analogue)
ATC: H01BA04 (Systemic hormonal preparations, excluding sex hormones and insulins | Posterior pituitary lobe hormones | Vasopressin and analogues)
Use during pregnancy only on medical advice.
Terlipressin is a hospital medicine used in serious situations such as bleeding from oesophageal varices and hepatorenal syndrome in patients with advanced liver disease. It is a vasopressin analogue that narrows vessels in the splanchnic circulation, reducing pressure in the portal system and sometimes helping kidney function in a liver-disease context.
It is given intravenously only by healthcare professionals, with close monitoring. It is not a home treatment. The dose and duration depend on the indication, body weight, kidney function, respiratory status and severity of liver disease. In hepatorenal syndrome, the doctor carefully weighs the benefit because some patient groups have higher risk of serious events.
Side effects may include abdominal pain, diarrhoea, nausea, pallor, high or low blood pressure, slow heartbeat, headache and reduced circulation in the limbs. Severe reactions may occur, such as cardiac or intestinal ischaemia, rhythm disturbances, low sodium, respiratory failure or worsening breathing, especially in frail patients.
Tell healthcare staff immediately if chest pain, shortness of breath, blue lips, confusion, severe abdominal pain, cold painful hands or feet, palpitations or fainting occurs. Inform the doctor about heart disease, hypertension, asthma/COPD, infections, advanced kidney failure and all medicines used. Monitoring is essential during administration.